Stem Cell Theranostics and CapellaBio launch collaboration on cardiotoxicity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and Kymab announced a partnership in immuno-oncology research.

The program will be conducted with MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation unit. The partnership will focus on developing novel human therapeutic antibodies to treat a variety of cancers using Kymab’s Kymouse antibody discovery platform. The agreement is for an initial period of five years.

The ORBIT platform is a centralized organization within MD Anderson, which focuses on translating discoveries into clinically relevant anti-cancer mAbs. ORBIT’s scientific directors are Jeffrey Molldrem, professor of the Department of Stem Cell Transplantation and Cellular Therapy, and Michael Curran, professor of the Department of Immunology.

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login